comparemela.com

Latest Breaking News On - Hansoh pharma - Page 2 : comparemela.com

Silence Therapeutics to Participate in Fireside Chat at H C Wainwright 2nd Annual BioConnect Investor Conference

Silence Therapeutics plc, Nasdaq: SLN , an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines,.

Hansoh pharmaSilence therapeuticsAnnual bioconnect investor conference

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Published findings demonstrate zerlasiran was well-tolerated and significantly reduced Lp after single and multiple dosing .

United statesCurtis rambaranHansoh pharmaJournal of the american medical associationExchange commission onSilence therapeuticsAmerican medical associationChief medical officerSecurities litigation reform actAdmission documentAnnual reportExchange commission

Silence Therapeutics plc: Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Silence Therapeutics plc: Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomStefan klotterCraig toomanRhonda hellumsHansoh pharmaExchange commissionCorporate communicationsChief financial officerYear endSales agreementSecurities litigation reform actAdmission documentAnnual reportLassen sie

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Study met primary endpoint and demonstrated highly significant reductions in Lp to week 36 Lipoprotein reduction was consistent with phase 1 results Topline 48-week data expected in 2Q 2024 .

Steven romanoHansoh pharmaHead of researchExchange commission onSilence therapeuticsSecurities litigation reform actAdmission documentAnnual reportExchange commission

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Silence also announced positive topline 36-week data from ongoing phase 2 study of zerlasiran in patients with high lipoprotein Company to host conference call and webcast today at 8 a.m. EDT / 12.

United kingdomHansoh pharmaRhonda hellumsCraig toomanExchange commissionSilence therapeuticsChief financial officerYear endSales agreementSecurities litigation reform actAdmission documentAnnual report

vimarsana © 2020. All Rights Reserved.